IL327180A - קולטנים כימריים ממוקדי cd19/cd20 דו-ספציפיים ושימושיהם - Google Patents

קולטנים כימריים ממוקדי cd19/cd20 דו-ספציפיים ושימושיהם

Info

Publication number
IL327180A
IL327180A IL327180A IL32718026A IL327180A IL 327180 A IL327180 A IL 327180A IL 327180 A IL327180 A IL 327180A IL 32718026 A IL32718026 A IL 32718026A IL 327180 A IL327180 A IL 327180A
Authority
IL
Israel
Prior art keywords
cell
car
cells
seq
amino acid
Prior art date
Application number
IL327180A
Other languages
English (en)
Inventor
Seung E Cha
Cokey Nguyen
Christina Pham
Original Assignee
Atara Biotherapeutics Inc
Seung E Cha
Cokey Nguyen
Christina Pham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atara Biotherapeutics Inc, Seung E Cha, Cokey Nguyen, Christina Pham filed Critical Atara Biotherapeutics Inc
Publication of IL327180A publication Critical patent/IL327180A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL327180A 2023-10-03 2024-10-02 קולטנים כימריים ממוקדי cd19/cd20 דו-ספציפיים ושימושיהם IL327180A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363587646P 2023-10-03 2023-10-03
PCT/US2024/049668 WO2025076144A1 (en) 2023-10-03 2024-10-02 Bispecific cd19/cd20-targeted chimeric antigen receptors and uses thereof

Publications (1)

Publication Number Publication Date
IL327180A true IL327180A (he) 2026-05-01

Family

ID=95283862

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327180A IL327180A (he) 2023-10-03 2024-10-02 קולטנים כימריים ממוקדי cd19/cd20 דו-ספציפיים ושימושיהם

Country Status (6)

Country Link
EP (1) EP4788705A1 (he)
KR (1) KR20260082322A (he)
CN (1) CN122122190A (he)
AU (1) AU2024355525A1 (he)
IL (1) IL327180A (he)
WO (1) WO2025076144A1 (he)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026107075A1 (en) * 2024-11-13 2026-05-21 Genentech, Inc. Methods of treating multiple sclerosis with cd19-cd20 dual car-t cells
WO2026107085A1 (en) * 2024-11-13 2026-05-21 Genentech, Inc. Methods of treating lupus with cd19-cd20 dual car-t cells
CN120795167B (zh) * 2025-04-15 2026-05-08 佰芮慷(广州)细胞医药科技有限公司 一种靶向人eb病毒的嵌合抗原受体car、car-nk细胞及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100232A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
KR102357312B1 (ko) * 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 결합 분자 및 그의 용도
US11535662B2 (en) * 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
IL326873A (he) * 2017-12-29 2026-04-01 Memorial Sloan Kettering Cancer Center קולטני אנטיגנים כימריים מוגברים ושימושיהם
MX2021002702A (es) * 2018-09-10 2021-05-12 Atara Biotherapeutics Inc Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas.
WO2024086842A2 (en) * 2022-10-21 2024-04-25 Memorial Sloan-Kettering Cancer Center Cells and compositions for treating cancer

Also Published As

Publication number Publication date
EP4788705A1 (en) 2026-08-12
AU2024355525A1 (en) 2026-04-02
KR20260082322A (ko) 2026-06-04
WO2025076144A1 (en) 2025-04-10
CN122122190A (zh) 2026-05-29

Similar Documents

Publication Publication Date Title
SG11202108759SA (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
SG11202100252SA (en) BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
HUE073404T2 (hu) CD19-et és CD20-at célzó kombinált kiméra antigén receptorok és azok alkalmazásai
GB2606869B (en) CLL1-Targeting chimeric antigen receptor and application thereof
SG11202100205UA (en) Ror-1 specific chimeric antigen receptors and uses thereof
IL274147A (he) נוגדנים וקולטני אנטיגן כימריים מוכווניי אנטיגן הבשלה של תאי b
IL283493A (he) נוגדנים דו-ספציפיים נגד-muc16 ונגד-cd28 ושימושים שלהם
IL287487A (he) קולטני אנטיגן כימיים עמידים לריטוקסימאב ושימושיהם
IL304554A (he) קולטני אנטיגן כימריים ביספציפיים הנקשרים ל- cd19 ו- cd22
SG11202109052YA (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
IL287156A (he) קולטני אנטיגן כימריים לקולטן 1 אנטי-פולאט אנושיים ושימושים בהם
IL312003A (he) קולטני anti-steap2 כימריים ושימושיהם
SG11202012155RA (en) Cd79a chimeric antigen receptors
IL281129A (he) שיטות והרכבים המכילים רצפטורים של אנטיגן כימרי b7h3
IL318416A (he) קולטי אנטיגנים כימריים ספציפיים ל-gprc5d ול-bcma
EP3240805A4 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP4174093A4 (en) FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING CD19 AND CD22 AND USE THEREOF
IL308361A (he) נוגדנים בעלי ספציפיות כפולה ושימושיהם
IL321365A (he) קולטן אנטיגן כימרי
IL279115A (he) מינון של נוגדן בי-ספציפי שקושר cd123 ו- cd3
EP4323387A4 (en) ENHANCED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
CA3306870A1 (en) Bispecific cd19/cd20-targeted chimeric antigen receptors and uses thereof
EP4041404A4 (en) HUMANIZED ANTI-ALPHA RECEPTOR 4 ANTIBODY (GRF-ALPHA-4) AND CHIMERIC ANTIGEN RECEPTOR (CAR)
CA3287693A1 (en) Bispecific chimeric antigen receptors targeting bcma and cd19
CA3270475A1 (en) Humanized anti-hla-g chimeric antigen receptors and uses thereof